Daratumumab, a human IgG1 monoclonal antibody that specifically binds to a unique epitope present on the CD38 molecule, induces, at least, a partial response in up to 30% of refractory multiple myeloma, due to its action on CD38-positive plasma cells, with a good safety profile.10 Here, CD38 is linked to plasma cell myeloma.